Recordati is a well-established international pharmaceutical group dedicated to the research, development, manufacturing, and marketing of pharmaceuticals with more than 4,300 employees and listed on the Italian Stock Exchange since 1984. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, in Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia.
Recordati offers a wide range of innovative pharmaceuticals - proprietary and under license - in a number of therapeutic areas including a specialized segment dedicated to treatments for rare diseases. An efficient field force of medical representatives and orphan drug representatives promotes its products in about 150 markets. The company’s leading products are drugs for the treatment of hypertension and other cardiovascular disorders as well as treatments for lower urinary tract disorders such as benign prostatic hyperplasia and urinary incontinence, treatments for metabolic diseases and since 2019 an innovative antipsychotic drug for the treatment of schizophrenia. Drugs for rare diseases are mainly treatments for endocrine and metabolic diseases of a genetic origin.
Oriented towards innovation and the sale of highly specialized products, the Recordati Group is the European partner of established international pharmaceutical companies.
Recordati focuses its research and development activities mainly in the area of rare diseases.
Recordati has six pharmaceutical production facilities - in Italy (Milan), France (Montluçon) Turkey (Çerkezköy), in Spain (Utebo - Zaragoza), Czech Republic (Pardubice) and Tunisia (Ariana) - two plants for the production of proprietary active ingredients – in Italy (Campoverde di Aprilia, Latina) and Ireland (Cork) and a packaging and distribution facility dedicated to rare disease products in France (Nanterre). Recordati produces active ingredients for both its own proprietary pharmaceuticals and for the international pharmaceutical industry.
The Group pursues a sustainable growth model, integrating social and environmental aspects into its corporate strategy and process, mindful that there can be no long-term economic development without responsible action.
2020 key consolidated data
Consolidated revenue € 1,448.9 million
Operating income € 469 million
Net income € 355 million
Expand through organic development and through acquisitions.
Reinforce presence in existing key markets.
Develop product portfolio by enhancing product pipeline and new product acquisitions.
Develop the business dedicated to treatment of rare diseases on a worldwide basis.